Top Stories
-
New Columbia research suggests that targeting neighboring bone cells may be a better strategy than targeting malignant stem cells to treat acute myeloid leukemia.
-
In the face of daunting disparities in health care, the medical community can take small steps that make a difference, a Columbia orthopedic surgeon writes.
Topic
-
The National Cancer Act, signed into law Dec. 23, 1971, funded the expansion of cancer research and care at Columbia. Today, with plans for a new clinical building, the future looks bright.
Topic
-
Innovation and discovery are at the heart of Herbert Irving Comprehensive Cancer Center's mission to reduce the burden of cancer. Learn more in the HICCC's 2021 annual report.
Latest News
- July 3, 2019
Researchers in Columbia's medical and engineering schools have edited a strain of non-pathogenic bacteria to colonize solid tumors in mice and safely deliver potent immunotherapies.
- June 19, 2019
Barring ovarian cancer surgery at low-volume hospitals could limit access to care for many rural and underserved patients, a new study has found.
Topic
- April 25, 2019
At Columbia, patients with brain cancer will be able to participate in a new type of clinical trial that promises to speed up the development of better drugs for glioblastoma.
Topic
- April 17, 2019
Leading physician and researcher, Lisa Kachnic, MD, will lead Columbia's department of radiation oncology.
Topic
- April 3, 2019
Anil Rustgi, the new director of the Herbert Irving Comprehensive Cancer Center, talks about new ideas in cancer research, the best patient care, and the importance of physician-scientists.
- February 20, 2019
A clinical trial at Columbia and other centers found that patients responded to a new “smart drug” for women with an aggressive form of breast cancer.
Topic
- February 15, 2019
Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
Topic
- January 17, 2019
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for the viruses.
Topic
- December 19, 2018
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
- December 10, 2018
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
